J&J sells pain reliever franchise for $1B; Eyecare company announces results of PhIII trial;

>J&J's ($JNJ) sale of the Nucynta franchise of non-opioid pain relievers for $1 billion has closed. Depomed ($DEPO) acquires various formulations of the medication, including extended release and immediate release versions, as well as an unlaunched oral formulation. The franchise generated sales of $172 million in 2014. More

> Kala Pharmaceuticals said its nanoparticle formulation to treat inflammation and pain following cataract surgery met all its primary efficacy endpoints in a Phase III trial. More

> Particle Sciences has received a patent for its SATx drug delivery platform to combine nanoparticles with surface-bound large molecules. More

> Cynapsus Therapeutics, a developer of sublingual thin film strips for Parkinson's, announced the completion of a $21 million financing round led by OrbiMed, Aisling Capital and Venrock. The company hopes to file a New Drug Application in 2016. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.